Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NDV-3A · 1 trial · 1 indication
Change in incident Staphylococcus aureus nasal colonization by study day 56 in a population of US Army trainees at Ft. Benning, GA
| Arm | Type | Description |
|---|---|---|
| NDV-3A | ACTIVE_COMPARATOR | 0.5 mL dose containing 300 micrograms of recombinant Als3 protein in phosphate-buffered saline and 0.5 mg aluminum as aluminum hydroxide |
| Placebo | PLACEBO_COMPARATOR | 0.5 mL dose containing phosphate-buffered saline and 0.5 mg aluminum as aluminum hydroxide |
| Name | Type | Description |
|---|---|---|
| NDV-3A | BIOLOGICAL | Single dose administered by intramuscular injection |
| Placebo | BIOLOGICAL | Single dose administered by intramuscular injection |
Inclusion Criteria: * Active duty, male subject, 17-35 years of age, inclusive, at the time of screening. * Assigned to one of the selected companies/battalions * Informed of the nature of the study and has agreed to and is able to read, review, and sign the informed consent document prior to scree...
NDV-3A is an investigational monoclonal antibody being developed for the prevention of Staphylococcus aureus colonization. It is intended for use in infectious disease, specifically targeting S. aureus. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
NDV-3A targets Staphylococcus aureus, a bacterium that can cause serious infections. As a monoclonal antibody, it is designed to prevent S. aureus colonization, which is the first step in establishing an infection. The drug is being studied for its ability to reduce the presence of this pathogen in at-risk individuals.
NDV-3A is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug for preventing Staphylococcus aureus colonization.
NDV-3A is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being studied for its potential to prevent Staphylococcus aureus colonization, and its safety and efficacy are still being evaluated in clinical trials.
NDV-3A has been studied in one completed Phase 2 clinical trial with the identifier NCT03455309. This trial, titled 'Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization,' enrolled 382 participants in the United States. The study was randomized, double-blind, and placebo-controlled, and included healthy male volunteers aged 17 years and older.